The carcinogenic role of high-risk human papillomavirus (HR-HPV) types in the increasing subset of vulvar intraepithelial neoplasia and vulvar cancer in young women has been established. However, the actual number of vulvar cancer cases attributed to HPV is still imprecisely defined. In an attempt to provide a more precise definition of HPV-driven vulvar cancer, we performed HPV-type-specific E6*I mRNA analyses available for 20 HR-/ possible HR (pHR)-HPV types, on tissue samples from 447 cases of vulvar cancer. HPV DNA genotyping was performed using SPF10-LiPA 25 assay due to its high sensitivity in formalin-fixed paraffin-embedded tissues. Data on p16 INK4a expression was available for comparative analysis via kappa statistics. The use of highly sensitive assays covering the detection of HPV mRNA in a broad spectrum of mucosal HPV types resulted in the detection of viral transcripts in 87% of HPV DNA+ vulvar cancers. Overall concordance between HPV mRNA+ and p16 INK4a upregulation (strong, diffuse immunostaining in 425% of tumor cells) was 92% (K = 0.625, 95% confidence interval (CI) = 0.531-0.719). Among these cases, 83% were concordant pairs of HPV mRNA+ and p16 INK4a + and 9% were concordant pairs of HPV mRNA − and p16 INK4a − . Our data confirm the biological role of HR-/pHR-HPV types in the great majority of HPV DNA+ vulvar cancers, resulting in an HPV-attributable fraction of at least 21% worldwide. Most HPV DNA+ vulvar cancers were associated with HPV16 (85%), but a causative role for other, less frequently occurring mucosal HPV types (HPV26, 66, 67, 68, 70 and 73) was also confirmed at the mRNA level for the first time. These findings should be taken into consideration for future screening options as HPV-associated vulvar preneoplastic lesions have increased in incidence in younger women and require different treatment than vulvar lesions that develop from rare autoimmune-related mechanisms in older women.
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With an annual incidence of 2 cases per 100 000 women, vulvar cancer is a rare malignancy. 1, 2 The estimated global burden of vulvar cancer is 27 000 cases annually and it accounts for 3-5% of all gynecological cancers in developed countries. 3 Most cases of vulvar cancer present as squamous cell carcinoma (490%). 1, 2 The International Agency for Research on Cancer and World Health Organization distinguish two pathways for the development of vulvar cancer. The first pathway is activated by underlying autoimmune-related processes while the second pathway is triggered by mucosal human papillomavirus (HPV) infection. Differentiated-type vulvar intraepithelial neoplasia is non-HPV associated and appears in older women (median age 70 years) who develop chronic inflammation of the anogenital area often diagnosed as lichen sclerosus or lichen planus. 4 In 2-5% of cases, these lesions further develop into differentiated keratinizing squamous cell carcinoma of the vulva. 5 Usual-type vulvar intraepithelial neoplasia is HPV associated and appears in younger women. Morphologically, it can be either basaloid, warty or mixed histology, and if untreated, 9-16% of lesions can progress to basaloid or warty squamous cell carcinoma of the vulva. 5 In some countries, HPV-associated vulvar intraepithelial neoplasia increased four-fold between 1973 and 2000, particularly among younger women (median age 40 years). 6, 7 Changes in sexual behavior, early onset of sexual activities and transmission of highrisk/possible high-risk HPV types (HR-/pHR-HPV), especially HPV16, are considered contributing factors to this observed increase in vulvar lesions.
Differentiating between HPV-associated and non-HPV-associated vulvar lesions has been recognized as an important distinction among clinicians as it has both therapeutic and postoperative management implications. [8] [9] [10] Non-HPV-associated vulvar intraepithelial neoplasia is a rapidly progressive lesion requiring immediate excision and treatment. 8 By contrast, HPV-associated vulvar intraepithelial neoplasia develops slowly and can spontaneously regress or regress postlocalized treatment (eg, with topical immune modulators). 8, 10 However, patients with HPV-associated vulvar lesions are at increased risk of developing additional HPV-associated lesions within the anogenital tract. Consequently, careful examination and monitoring of the cervix and the perianal area is needed in these women. 11 True estimation of the HPV-attributable fraction in vulvar cancer is still imprecise. World estimation of HPV DNA-positive (HPV DNA+) vulvar cancers stands currently at 43%. 3 This estimation is based on a recent meta-analysis that assessed 63 epidemiological studies including the evaluation of 1873 vulvar cancer cases collected from across the globe. 12 However, the mere presence of HPV DNA has shown to be insufficient to define HPV-driven mucosal cancers outside of the cervix. [13] [14] [15] [16] Previously, we compared HPV DNA positivity alone and in combination with p16 INK4a upregulation by assessing these markers directly in 1709 vulvar cancer tissue specimens collected from 39 countries worldwide. 17 Our results showed a lower fraction of HPV DNA+ vulvar cancers compared with previous HPV DNA reports; 29% 17 versus 43% based on a meta-analysis. 3 In addition, adding p16 INK4a upregulation data to the sole HPV DNA presence in tumor tissues lowered estimate of the HPV-attributable fraction of vulvar cancer from 29% to 25%. 17 In the continuous effort to better define HPVdriven vulvar cancer, we focused on collecting biological evidence of HPV-transformed phenotype in the vulva by investigating the expression and concordance of HPV mRNA and p16 INK4a in 447 HPV DNA+ cases of vulvar cancer. Making this distinction is particularly important toward the adequate assessment of potential clinical differences between HPV-driven and non-HPV-driven malignancies of the vulva.
Materials and methods

Ethics Statement
The samples obtained and analyzed here were selected from HPV VVAP (International Survey on HPV prevalence and type distribution in Vulvar, Vaginal, Anal, Penile neoplasias) 17 for which the Institutional Review Board approval was received. All samples were anonymized. All protocols applied were approved by local and Catalan Institute of Oncology ethics committees.
Study Approach
All specimens analyzed were formalin fixed and paraffin embedded. Vulvar cancer cases with sufficient tissue quality and quantity that had been previously analyzed for the presence of HPV DNA and p16 INK4a 
HPV mRNA Analysis
The mRNA extraction and mRNA detection from tissue ribbons were performed as previously described. 18, 19 For all cases analyzed, hematoxylin and eosin stain before and after sectioning for RNA showed ≤ 10% tumor reduction. For each case, HPVtype-specific E6*I mRNA RT-PCR assays were performed for an HPV type(s) previously determined by genotyping and for a cellular ubiquitin C gene as a control for tissue quality. A second assay was performed to assess the presence of HPV16 E6*I mRNA in all cases, irrespective of HPV DNA result. Cases with HPV mRNA positive (HPV mRNA+) and/or ubiquitin C mRNA+ signal were considered 'RNA valid'. All 'RNA invalid' samples, ie, cases that were HPV mRNA-negative (HPV mRNA − ) and ubiquitin C mRNA − , were analyzed a second time, and according to signals obtained, classified as 'RNA valid' or 'RNA invalid'. Of the 11 vulvar cancer cases initially classified as 'RNA invalid', six cases were reclassified as 'RNA valid' and five remained classified as 'RNA invalid' upon re-analyses.
Testing for HPV type mRNA in HPV DNA-negative (HPV DNA − ) cases was not included as part of the primary scope of this work owing to the complexity of such analyses (Figure 1 ). However, a subset of 20 HPV DNA − cases were tested for HPV16 E6*I mRNA as a negative control (10 HPV DNA − / p16 INK4a − and 10 HPV DNA − /p16 INK4a + cases). The 10 HPV DNA − /p16 INK4a − cases were 'RNA valid' and also HPV16 mRNA − . From 10 HPV DNA − /p16 INK4a +, 9 were 'RNA valid' and 3 of the 9 were HPV16 mRNA+ (33%). This observation had minimal impact on overall estimates owing to the small number of p16 INKa + cases among the HPV DNA − cases (9%; 103 of 1, 194 
Results
A total of 1709 vulvar cancer cases collected from 39 countries were HPV genotyped; 29% (488/1709) of these cases were HPV DNA+ ( Figure 1 ). 17 From 488 HPV DNA+ cases, 447 were analyzed in the current study for the expression of viral mRNA and 99% (442/447) were 'RNA valid' (HPV mRNA+ and/or ubiquitin C mRNA+) ( Table S1 ). The biological activity of HPV26, 66, 67, 68, 70 and 73 in vulvar cancer was confirmed by the presence of HPV-type mRNA and upregulation of p16 INK4a . Two HPV53 single DNA+ cases were HPV53 mRNA − and p16 INK4a − .
Twenty-nine 'RNA valid' vulvar cancers harboring DNA of multiple HPV types were identified of which 83% (24/29) were HPV mRNA+ for at least one HPV type identified by genotyping (Table 1 and Table 3 ). From these 29 cases, 10 could be fully analyzed (ie, mRNA assays were available for all the types detected by genotyping). Overall, 40% (4/10) of these cases expressed transcripts of multiple HR-/pHR-HPV types ( (Table 4) . McNemar tests (P = 0.868) indicated that the discordant cases are equally distributed. Furthermore, there was no difference in kappa index concordance between histological diagnosis, region of origin or year of diagnosis (Table 2) . However, differences in kappa index concordance were observed according to age group; agreement being higher among women aged 466 years compared with women aged o 66 years ( Table 2) .
Cutoff for p16 INK4a in HPV-Driven Vulvar Cancer
To define p16 INK4a upregulation in vulvar cancer, we used the cutoff of 425% p16 INK4a + tumor cells, with strong staining intensity and in a diffuse pattern. As there is no current standardization for p16 INK4a cutoff to define HPV-associated vulvar cancer, we challenged our 425% cutoff by different scenarios as shown in Tables 4 and 5 . The 425% cutoff showed 83% (360/433) of HPV DNA+/HPV mRNA+ tumors to be p16 INK4a +, yielding good agreement between p16 INK4a and HPV mRNA positivity (Table 4) . Increasing this cutoff to 450% or 475% resulted in a fair and poor agreement between p16 INK4a and HPV mRNA positivity, respectively (Table 4) . With 425% cutoff, 94% of HPV DNA +/HPV mRNA+ keratinizing tumors were defined as p16 INK4a + compared with only 44% when 475% cutoff was applied (Table 5 ). This difference was lower for non-keratinizing vulvar cancers where 95% of non-keratinizing HPV DNA+/HPV mRNA+ tumors were defined as p16 INK4a + with 425% cutoff against 71% with 475% cutoff (Table 5) . Keratinizing vulvar cancers tend to present with a lower percentage of p16 INK4a + tumor cells, compared with non-keratinizing vulvar cancers (Table 5) Table 2 ). Prevalence of HPV DNA+/HPV mRNA +/p16 INK4a + cases varied by geographic region with the highest prevalence observed in Oceania (91%) and the lowest in Africa (59%) ( Table 2 ). In addition, the total number of vulvar cancer cases from Africa Biomarkers of HPV-driven vulvar cancer (n = 17) was also low in comparison with Oceania (n = 75) ( Table 2) . HPV DNA+/HPV mRNA+/p16 INK4a + vulvar cancers varied across five age groups and ranged between 78% (≥81 years) and 86% (o 66 years) ( Table 2 ).
Discussion
The etiological role of HPV in the development of vulvar cancer has been well recognized. 1 However, the true attributable fraction of HPV in vulvar cancer remains unclear. It has become increasingly evident that a functional evidence of HPV activity or HPV transformation is necessary in addition to the HPV DNA presence, in order to define true HPV-driven tumors outside of the cervix uteri. 20 In our study, we focused on obtaining evidence of HPV transcriptional activity, ie, the presence of HPV mRNA in HPV DNA+ vulvar cancer tissues. In an examination of 447 HPV DNA+ vulvar cancers, we combined HPV mRNA data with data on a well-established marker of HPV-transformed phenotype in mucosal cancers, p16 INK4a . Viral mRNA was identified in 87% of the HPV DNA+ vulvar cancer cases. Among the 433 cases with both HPV mRNA and p16 INK4a data available, 83% were concordant pairs of HPV mRNA+ and p16 INK4a +. These data indicate that a proportion of HPV DNA+ cases (9%) does not express an additional marker of HPV activity, therefore questioning HPV attribution in that subset. Thus, in the absence of mechanistic data to define an HPV-driven cancer, markers of HPV activity and HPV-transformed phenotype demonstrated in addition to HPV DNA, should allow for more robust etiologic attribution. To identify transcriptionally active HPV types in vulvar lesions, we applied HPV-type-specific and highly sensitive E6*I mRNA assays developed for 20 HR-/pHR-HPV types and validated for use in formalin-fixed paraffin-embedded tissues. 18, 21 HPV transcripts are indicative of active virus but are not transformation specific. 22, 23 But the expression of viral mRNA in mucosal tumors is a requirement for expression of E7 oncoprotein, which drives malignant transformation and induces p16 INK4a upregulation. Our study is not the first to examine the expression of viral transcripts in vulvar lesions. However, in terms of the number of cases and range of HPV types analyzed, it is the broadest in scope. We identified eight earlier studies that provided data on viral E6/E7 transcripts in vulvar lesions, which focused on HPV16 and/or HPV18 transcripts only. [24] [25] [26] [27] [28] [29] [30] [31] Our study also demonstrates that HR-HPV types other than HPV16 and 18, as well as a subset of pHR-HPV types, have an etiological role in the development of vulvar cancer.
Expression of p16 INK4a protein in vulvar preneoplastic lesions and vulvar cancer has also been assiduously investigated. 2, 27, [32] [33] [34] [35] In the context of HPV infection, p16 INK4a upregulation is a result of a cellular defense mechanism referred to as 'oncogeneinduced senescence'. 36 In cell lines of cervical cancer, an HPV-transformed tumor model, CDKN2A gene that encodes for p16 INK4a protein is present as a wild-type, and p16 INK4a upregulation is induced by HR-HPV E7 oncogene expression. [36] [37] [38] In the vulva, up to 20% of cancers carry CDKN2A mutations but these are usually 'silencing' mutations primarily identified in HPV DNA − cancers and resulting in a loss of p16 INK4a expression. 39, 40 This confirms the value of p16 INK4a upregulation as a marker of HPVtransforming activity in vulvar cancer in addition to HPV DNA and/or HPV mRNA or as a single marker once the precise cutoff has been defined.
Numerous immunohistochemical studies have confirmed p16 INK4a upregulation as an excellent biomarker to define HR-HPV-associated lesions at different mucosal sites. 13, 15, 21, [41] [42] [43] [44] In the vulva, p16 INK4a also seems to be a superior marker to assess the effectiveness of imiquimod treatment suggested for HPV DNA+ vulvar intraepithelial neoplasia. 10, 45 Our findings demonstrate p16 INK4a upregulation in all HPV DNA+/HPV mRNA+ vulvar cancers harboring single pHR-HPV types 26, 66, 67, 70 or 73 (1 case each) and HPV DNA+ (no RNA assay available) pHR-HPV types 30 (1 case) or 69 (2 cases). These HPV types are not included in commercial HPV genotyping assays and might be missed when analyzing for HPV DNA only. However, the likelihood of identifying such cases is very low (o 2%). The specificity of p16 INK4a upregulation in support Table S2 ). In this single LR-HPV6 DNA+/p16 INK4a + vulvar cancer case in our study (with low-intensity p16 INK4a staining in 475% of tumor cells), HPV6 DNA was found in tumor cells, and not in the surrounding stroma, speculating that LR-HPV6 might be just less efficient in inducing p16 INK4a upregulation. 46 In such cases, as well as cases discordant for HPV mRNA and p16 INK4a expression, investigation via CDKN2A gene sequencing should be explored in future studies. It is also possible that, in such cases, HPV DNA or HPV mRNA are present below detection limits of the applied assays. Or perhaps p16 INK4a upregulation was a consequence of a CDKN2A gene mutation, although such CDKN2A mutations seem to be rare in vulvar malignancies. 39, 40 The cutoff for upregulation of p16 INK4a , as a biomarker to identify HPV-associated vulvar lesions, has not been specifically defined. The Lower Anogenital Squamous Terminology Standardization Project for HPV-Associated Lesions recommends when p16 INK4a should be used in combination with histology to describe HPV-associated precancerous lesions. 47, 48 The experts suggest that strong and diffuse, block-positive p16 INK4a result should be used to support a categorization of precancerous disease. 47, 48 However, no percentage of p16 INK4a + tumors cells has been specified as a guideline to help define HPV-associated vulvar cancer. In this study, we have applied a cutoff including 425% of p16 INK4a +-stained tumor cells in a diffuse pattern and with high staining intensity. This cutoff was meticulously defined by a team of expert pathologists in a study on 321 cervical cancers. 21 To test how the distribution of HPV-associated vulvar cancers would change if that cutoff would be increased, we have tested different scenarios (Tables 4 and 5 ). We found that keratinizing vulvar cancers, the most common histological subtype in this cancer series, 17 were affected the most when cutoff for p16 INK4a positivity was 425%. Application of 475% cutoff to define p16 INK4a positivity resulted in 66% of HPV DNA+/HPV mRNA+ keratinizing tumors to be classified as p16 INK4a − , compared with only 6% when 425% p16 INK4a cutoff Biomarkers of HPV-driven vulvar cancer G Halec et al was applied. If p16 INK4a positivity would be the only biomarker to assess HPV association, these cancers would be classified as non-HPV associated. Similar observation was made for non-keratinizing tumors but to a lesser extent-27% of HPV DNA+/HPV mRNA+ non-keratinizing tumors were to be classified as p16 INK4a − with 475% cutoff, in contrast to 5% with 425% cutoff. As HPV DNA and HPV mRNA expression are considered to precede the upregulation of p16 INK4a in HPV-associated mucosal tumors, the lack of correlation between high percentage of p16 INK4a + tumor cells and HPV mRNA positivity in this vulvar cancer series remains to be investigated. At present, we conclude that lower percentage of p16 INK4a +-stained tumor cells is associated with a degree of keratinizing component, an observation already made in our series of 321 cervical cancers. 21 A single study by Riethdorf et al 27 also correlated the use of HPV mRNA and p16 INK4a expression in vulvar lesions and found 90% (52 of the 58) of vulvar intraepithelial neoplasia and vulvar cancer cases to be HPV16 mRNA+/p16 INK4a +. More specifically, the authors showed that 31% of vulvar cancers were HPV16 mRNA+ while 34% were p16 INK4a +. 27 In our study, the HPV mRNA+ and p16 INK4a + concordance among vulvar cancers yielded good agreement (K = 0.625, 95% CI: (0.531-0.719)), with 83% concordant pairs of HPV mRNA+ and p16 INK4a + and 9% concordant pairs of HPV mRNA − and p16 INK4a − . HPV DNA+/HPV mRNA +/p16 INK4a + vulvar cancers did not significantly vary among different age groups or different time periods. The highest fraction of HPV DNA+/HPV mRNA +/p16 INK4a + vulvar cancers was identified in Oceania (92%) and the lowest in Africa (59%), which was significantly different. However, we cannot exclude that this difference might be due to the number of cases available from these two continents (Africa: n = 17 versus Oceania: n = 82).
A clear definition of HPV-driven vulvar cancer is important for assessing potential clinical differences in HPV-associated vulvar cancers compared with those vulvar cancers that develop through autoimmune processes. Clinical studies have demonstrated better overall and disease-free survival for patients with HPV-associated head-and-neck 15 51, 52 lower in-field relapse 51 and lower recurrence rate 50 compared with vulvar cancers that were p16 INK4a − . It remains to be seen whether classifying HPV-driven vulvar cancers through HPV mRNA positivity together with p16 INK4a upregulation should further improve the classification and evaluation of HPV-driven versus non-HPV-driven vulvar cancers.
Although the set of vulvar cancer cases analyzed here represents the collection of tissue samples worldwide, our study is limited by the small number of cases originating from North America and Africa (o 5% of all cases) as opposed to the other four continents. Other limitations include the absence of fully functional data for all of the samples tested as we did not analyze the transcriptional activity of pHR-HPV30 and 69 or LR-HPV types, for which no E6*I mRNA RT-PCR assays have been developed. In addition, as our study is not population based, there remains a question of potential selection bias. However, we believe that this is unlikely as the cases selected were obtained from large pathology laboratories some of which served as the unique national laboratory for the country. In addition, we requested that selection of consecutive cases should be based on an overall diagnosis of vulvar cancer or on the availability of tissues in a given period without any additional selection criteria, such as 'histology' or 'age'. 17 The biggest asset of the present study is the contribution of HPV mRNA data, in addition to the provision of data on p16 INK4a expression in vulvar cancer; in this regard, the study undertakes the task of providing a more reliable description of vulvar cancers with HPV-transformed phenotype. The estimate of HPV attribution in vulvar cancer in our study is lower when compared with previous HPV DNA reports and meta-analyses. 3 This might be due to the use of: (i) strict HPV protocols and different laboratories to avoid potential cross-contamination during regulated procedures (tissue sectioning, DNA and RNA extraction, PCR, RT-PCR and Luminex hybridization); (ii) control samples for assessing potential cross-contamination; and (iii) additional markers indicative of active virus in addition to the sole HPV DNA presence. Finally, a clear and accurate characterization of HPV-driven tumors is the essential starting point to define possibly required altered approaches in patient management or evaluation of therapeutic response. 
